PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2017
June 12 2017 - 4:01PM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, today announced
that several of its experts will discuss key issues facing the
industry at the 53rd Drug Information Association (DIA) Annual
meeting, held from June 18 to 22, 2017 in Chicago.
PAREXEL will hold in-booth presentations and technology
demonstrations at booth 820 in the exhibit hall. Company experts
will share several formal presentations during the program,
including:
Sunday, June 18
- 1 p.m.: (Short Courses) “Japan
Regulatory Environment: Overview of the Organization, Processes,
Systems, and Changes Affecting Pharmaceutical Development,” Alberto
Grignolo, Corporate Vice President, PAREXEL Consulting
Monday, June 19
- 1:15 p.m.: (Track 13 – Innovation
Theater) “Developing Drugs in the New Era of Personalized
Medicines,” Sy Pretorius, Senior Vice President and Chief
Scientific Officer, Anita Nelsen, Senior Director and Head of
Genomic Medicine Services
Tuesday, June 20
- 10:30 a.m.: (Track 1 – Big
Data/eHealth) “Evolving Data Standards and Regulations,” Michael
Goedde, Vice President, Clinical Data Management and Database
Programming
- 2 p.m.: (Track 1 – Big Data/eHealth)
“Obtaining Better Outcomes with Unstructured/Structured Data: How
to Improve Clinical, Regulatory, and Commercial Convergence,” David
Kiger, Vice President, Product Strategy
- 4 p.m.: (Track 7 – Special Populations)
“Oncology Trials: A Study in Adaptation,” Sharon Murray, Associate
Director, Biostatistics
Wednesday, June 21
- 10:30 a.m.: (Track 1 – Big
Data/eHealth) “My Fitbit Heart Rate Data is Clinical Trial Grade,
Right?” Keith Wenzel, Senior Director, Solution Incubator
- 2 p.m.: (Track 4 – Patient Engagement)
“Patient Engagement: Holy Grail or a Passing Fad?” Keith Wenzel,
Senior Director, Solution Incubator
To schedule a briefing with a PAREXEL subject matter expert at
DIA 2017, email events@parexel.com. For more information about
PAREXEL visit booth 820 during the meeting or www.PAREXEL.com.
Information about the DIA 2017 can be found at www.diahome.org.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services company, providing a broad range of
expertise-based clinical research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology, and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170612005930/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorKathryn McMahon, PAN CommunicationsTel.: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024